QA: Foghorn Therapeutics Inc in us_pharma/2024

Table of Contents

See also this year's filing and all EDGAR filings for this company.

PDF Report 0001822462_2025_Foghorn_Therapeutics_Inc.pdf

Logs

Graph

Absolute values for 0001822462, Foghorn Therapeutics Inc

  xvar xval
0 AssetsCurrent 249,601,000
1 IntangibleAssetsNetIncludingGoodwill 0
2 PropertyPlantAndEquipmentNet 0
3 remainder_Assets 34,381,000
4 LiabilitiesCurrent 66,989,000
5 LiabilitiesNoncurrent 262,521,000
6 remainder_Liabilities 0
7 CostOfGoodsAndServicesSold 0
8 SellingGeneralAndAdministrativeExpense 20,860,845
9 ResearchAndDevelopmentExpense 83,417,572
10 remainder_Expenses 2,958,321
11 remainder_Revenues 19,638,905
12 remainder_NetIncome 18,700,819
13 remainder_ComprehensiveNetIncome 1,945,635
  yvar yval
0 Assets 283,982,000
1 Liabilities 329,510,000
2 Expenses 107,236,738
3 Revenues 19,638,905
4 StockholdersEquity -45,528,000
5 NetIncome -68,897,014
6 ComprehensiveNetIncome -67,924,196
7 BaseVar 380,507,048
8 EconomicCapitalRatiobeforeLimitedLiability -0.545
9 EconomicCapitalRatio 1.38

Edgar->Model Mapping

Feature Distribution

Change over Time